As Form Health's Chief Medical Officer Florencia Halperin points out, it's exciting to see the first generic GLP-1 agonist come to market. However, there is still work to do to ensure that obesity medications are affordable and available in appropriate dosages to treat obesity. At Form Health, obesity medication is just one part of our science-based, comprehensive approach that helps patients achieve weight loss and improved health. Is your organization seeking an impactful and cost-effective obesity solution? Contact us at [email protected] to learn how we can help.
The first generic GLP-1 receptor agonist has entered the market! Generic liraglutide is now manufactured and sold by Teva, and is available at pharmacies for patients. While this is an exciting development, and perhaps the first real opportunity to see drug prices start to come down, we are not there yet. It was disappointing to learn that the cost is about $700/month, compared to brand name Victoza at around $800/mo. Also, what has become generic is the diabetes dosing (max 1.8 mg per day), not the obesity dosing (3 mg/day) we typically use in our practice. In about 6 mos other companies may also make generic liraglutide at this dose, and perhaps then we will see the price come down more significantly. It would be amazing to start to see lower costs for these medications that can be so impactful but are also so prohibitively expensive!